In the labyrinthine ecosystem of a growing tumor, not all cellular residents are sworn enemies. Macrophages, the immune system’s versatile janitors and sentinels, are notorious for their dual allegiances, sometimes fiercely attacking malignant cells and other times, with tragic complicity, nurturing their spread. Lung adenocarcinoma, a subtype of non-small cell lung cancer and one of the leading causes of cancer mortality worldwide, is a master at exploiting this betrayal. For years, researchers have observed that dense infiltrates of tumor-associated macrophages (TAMs) correlate with poor prognosis and heightened metastatic dissemination, yet the precise molecular switch that transforms these guardians into collaborators remained maddeningly elusive. Now, a breakthrough study published in Cell Death Discovery by Feng and colleagues has illuminated a stunningly detailed biochemical highway that runs from a metabolic enzyme in macrophages straight to the deadly machinery of metastasis, identifying a critical node involving a molecule called UPP1 that choreographs a deadly dance of mitochondrial stress and inflammatory alarms.
The research centers on uridine phosphorylase 1 (UPP1), an enzyme previously known for its humble housekeeping role in the salvage pathway of pyrimidine nucleosides. UPP1 catalyzes the reversible phosphorolysis of uridine to uracil and ribose-1-phosphate, thereby helping the cell maintain a balanced nucleotide pool. While UPP1 has been implicated in the metabolism of fluoropyrimidine chemotherapeutics like 5-fluorouracil, its direct role in cancer progression, particularly within the stromal immune compartment, had been largely overlooked. Feng’s team, however, dug deep into transcriptomic datasets from human lung adenocarcinoma specimens and made a startling observation: UPP1 expression was dramatically upregulated not in the cancer cells themselves, but specifically in the infiltrating macrophages. This elevation was further magnified in metastatic lesions compared to primary tumors, suggesting a functional link between macrophage-intrinsic UPP1 activity and the grim capacity of cancer cells to colonize distant organs. The specificity of this upregulation immediately hinted at a novel regulatory mechanism that the tumor microenvironment must be hijacking.
To dissect the functional consequences of this enzymatic surge, the investigators employed a sophisticated array of in vivo and in vitro models. Using syngeneic mouse models of lung adenocarcinoma, they demonstrated that genetic deletion of UPP1 specifically in myeloid cells—the precursors of macrophages—dramatically reduced the number and size of metastatic nodules in the lungs, while primary tumor growth remained largely unaffected. This elegant experiment revealed that UPP1 was not a general promoter of proliferation but a selective enabler of the metastatic cascade. Complementary assays with bone marrow-derived macrophages showed that overexpression of UPP1 endowed these cells with a pro-metastatic secretory profile, enhancing the migration and invasiveness of co-cultured cancer cells through extracellular matrix barriers. The team then leveraged state-of-the-art single-cell RNA sequencing to map the transcriptional landscape of TAMs, uncovering that UPP1-high macrophages adopted a distinct functional state characterized by a pronounced glycolytic shift and an inflammatory gene signature, setting the stage for the discovery of the underlying signaling axis.
The central mystery now became: how does a humble pyrimidine salvage enzyme ignite such a malignant transformation in macrophages? The answer lay buried deep within the cell’s powerhouses. Feng and colleagues meticulously traced the metabolic fallout of UPP1 upregulation and found a dramatic surge in mitochondrial reactive oxygen species (mtROS). The biochemical logic here is fascinating: UPP1’s catalysis does not merely produce uracil; it also generates ribose-1-phosphate, a sugar phosphate that, through a series of metabolic interconversions, can feed into the pentose phosphate pathway and glycolysis, creating a state of metabolic overload. This metabolic pressure, compounded by potential imbalances in nucleotide pools, appears to stress the mitochondrial electron transport chain, causing electrons to leak and react prematurely with oxygen to form superoxide radicals. The resulting mtROS are not merely passive indicators of damage; they are potent second messengers capable of oxidizing biomolecules and triggering a cascade of cellular alarms, in this case converting the macrophage into a factory of metastasis-promoting inflammation.
The researchers next connected this mitochondrial distress signal to one of the most ancient and powerful sentinel systems of the innate immune response: the cyclic GMP-AMP synthase (cGAS). Canonically, cGAS is a cytosolic DNA sensor that detects misplaced double-stranded DNA, such as that derived from pathogens or damaged self-nuclei, and synthesizes the cyclic dinucleotide 2’3’-cGAMP to activate the stimulator of interferon genes (STING) pathway. However, an emerging body of literature has shown that severe mitochondrial stress and mtROS can compromise the integrity of the mitochondrial membrane, leading to the release of mitochondrial DNA (mtDNA) into the cytoplasm. Feng’s team provided compelling evidence that this very phenomenon occurs in UPP1-overexpressing macrophages: the excessive mtROS triggered the release of oxidized mtDNA fragments, which directly engaged and activated the cGAS-STING axis. Fluorescence microscopy revealed the co-localization of cGAS with punctate mitochondrial remnants, and pharmacological scavenging of mtROS with Mito-TEMPO completely abrogated pathway activation, cementing the causal link from UPP1 metabolism to mtROS to cytosolic mtDNA leakage.
If cGAS-STING was the alarm bell, then the NLRP3 inflammasome was the devastating molecular cannon it fired. The study meticulously demonstrated that the cGAS-derived cGAMP, or perhaps the downstream signaling through STING, triggered the assembly of the NLRP3 inflammasome in the macrophages. This is a macromolecular complex that acts as a platform for activating caspase-1, which in turn cleaves the pro-inflammatory cytokines pro-interleukin-1β (pro-IL-1β) and pro-IL-18 into their mature, secretory forms, and also cleaves gasdermin D to induce a lytic, pro-inflammatory cell death known as pyroptosis. The team showed that UPP1-high macrophages exhibited robust NLRP3 oligomerization, caspase-1 activation, and a significant release of mature IL-1β into the tumor microenvironment. Blocking NLRP3 with the specific inhibitor MCC950 or genetically silencing it completely reversed the macrophage’s ability to promote cancer cell invasiveness, pinpointing this inflammasome as the downstream executioner of the metastatic program.
The secretion of IL-1β into the tumor microenvironment forms the linchpin of the metastatic circuit described in this work. IL-1β is a pleiotropic cytokine that triggers a cascade of changes in surrounding tissues, including the upregulation of matrix metalloproteinases (MMPs) that degrade the extracellular matrix, the expression of adhesion molecules on endothelial cells that facilitate tumor cell extravasation, and the activation of epithelial-to-mesenchymal transition (EMT) programs in cancer cells themselves. Feng’s experiments showed that conditioned media from UPP1-overexpressing macrophages, but not from their UPP1-deficient counterparts, could induce EMT markers such as vimentin and N-cadherin in lung adenocarcinoma cells, enabling them to acquire the spindle-shaped, motile morphology characteristic of cells primed for metastasis. This beautifully illustrates a paracrine loop where a metabolic switch in an immune cell (UPP1 upregulation) generates an inflammatory signal (IL-1β) that rewires the behavior of neighboring cancer cells, empowering them to venture out and colonize new territories.
A particularly striking aspect of the study was the elegant genetic and pharmacological dissection of the entire mtROS-cGAS-NLRP3 axis in vivo. By employing macrophage-specific knockout mice for UPP1, cGAS, and NLRP3, the team showed that each component was essential for the enhanced metastatic phenotype. For instance, mice bearing tumors with UPP1-deficient macrophages had significantly fewer lung metastases, and this protective effect was completely lost if those macrophages were forced to overexpress NLRP3 or were exposed to exogenous IL-1β, proving the mechanistic necessity of the pathway. Furthermore, pharmacological intervention with a UPP1 inhibitor, which the team identified through a small-molecule screen, markedly reduced metastatic burden in a therapeutic setting, even when administered after primary tumors were established. This provides a preclinical proof-of-concept that targeting macrophage UPP1 could be a viable anti-metastatic strategy, directly applicable to a type of cancer where metastatic recurrence is the primary cause of patient death.
What makes this discovery profoundly compelling from a clinical perspective is the identification of UPP1 as a candidate biomarker and a relatively selective Achilles’ heel. The analysis of human tissue microarrays corroborated the mouse data: high UPP1 expression in the stromal compartment, predominantly in CD68-positive macrophages, was strongly associated with advanced pathological stage, lymph node metastasis, and poor overall survival in a cohort of patients with lung adenocarcinoma. Since UPP1 expression in normal tissues is generally low and its function is part of a salvage pathway, therapeutic inhibition might exhibit a favorable toxicity window, sparing essential housekeeping functions in healthy cells while disarming the corrupted macrophages in the tumor. This potential selectivity addresses a major hurdle in immunomodulatory cancer therapy, where systemic activation or inhibition of immune pathways can lead to catastrophic autoimmune side effects.
The scientific narrative woven by Feng and colleagues also resonates deeply with the broader concept of “immunometabolism,” a field that has redefined our understanding of immune cell function by linking it inextricably to intracellular metabolic programs. Over the past decade, we have learned that pro-inflammatory M1-like macrophages are highly glycolytic, while anti-inflammatory M2-like macrophages rely on fatty acid oxidation. This study adds a rich new chapter, showing that a pyrimidine metabolism enzyme can sit upstream of mitochondrial reactive oxygen species and rewire the innate immune signaling from a wound-healing, anti-tumor state to a chronically inflamed, pro-metastatic state that paradoxically aids the tumor. It helps explain why purely anti-inflammatory strategies in cancer have yielded mixed results; the issue is not inflammation per se but the specific, maladapted mode of inflammation orchestrated by the tumor. The UPP1-driven cascade offers a precise molecular portrait of such maladaptation.
Nevertheless, the path from a groundbreaking mechanistic discovery in mouse models to a successful therapy in human oncology is notoriously arduous and littered with unforeseen obstacles. Targeting the mtROS-cGAS-NLRP3 axis requires exquisite precision because this very pathway is crucial for anti-viral and anti-bacterial immunity, as well as for the immunogenic cell death that makes some chemotherapy and radiation effective. Systemic inhibition of cGAS or STING could, in theory, render patients more susceptible to infections or dampen the therapeutic efficacy of standard-of-care treatments. Similarly, while the NLRP3 inhibitor MCC950 showed great promise in this study, clinical development of NLRP3 inhibitors for chronic inflammatory diseases has been slow due to concerns about hepatotoxicity and the complexity of targeting a central inflammatory node. The appeal of targeting UPP1 specifically lies in its conditional upregulation in the tumor microenvironment, but whether small-molecule inhibitors can achieve sufficient pharmacokinetic exposure in macrophage-rich metastatic niches without disrupting pyrimidine metabolism in bone marrow or other rapidly dividing tissues remains an open question for rigorous toxicology studies.
The team’s work also opens up a fascinating set of questions about the evolutionary logic of metabolic sensing within the innate immune system. Why would a uridine-cleaving enzyme be wired to a mitochondrial stress sensor and an inflammasome? One speculative but tantalizing possibility is that this axis originally evolved to detect metabolically stressed or dying cells during tissue injury or infection. Uridine and other nucleosides are released in abundance from apoptotic and necrotic cells, and macrophages might use UPP1 to sense this surge as a danger signal, coupling the presence of extracellular nucleosides to the need for a vigorous inflammatory response to clear debris and fight off any latent pathogens. In the context of cancer, tumor cells may treacherously exploit this primordial alarm system by generating a microenvironment rich in nucleosides and metabolic byproducts, thereby chronically coaxing macrophages into a state of pseudo-wound-repair that promotes not healing but tumor cell dissemination.
The immediate research horizon will likely see an explosion of studies aiming to validate and extend this axis across other cancer types and inflammatory diseases. The molecular tools generated by Feng’s team, particularly the conditional knockout mouse lines and the UPP1 inhibitor compound, will be invaluable for investigating whether a similar macrophage UPP1-mtROS-cGAS-NLRP3 cascade operates in specialties as diverse as pancreatic ductal adenocarcinoma, which is notoriously desmoplastic and rich in macrophages, or triple-negative breast cancer, where tumor-associated macrophages are prime drivers of metastasis. There is also the compelling possibility that UPP1 could serve as a therapeutic biomarker, enabling oncologists to stratify patients with early-stage lung adenocarcinoma who are at highest risk of occult metastasis and thus might benefit from adjuvant therapy targeting this immune-metabolic axis, a form of precision immunotherapy.
As the field moves forward, the integration of this axis with the established checkpoint immunotherapy landscape will be critical. Anti-PD-1/PD-L1 therapies can reinvigorate exhausted T cells within tumors, but their efficacy is often limited by an immunosuppressive stroma dominated by pro-tumorigenic macrophages. A therapeutic cocktail that combines a UPP1 inhibitor to “re-educate” macrophages away from their pro-metastatic, inflammatory phenotype with a checkpoint inhibitor to unleash T cell-mediated killing could theoretically yield a synergistic effect, transforming the overall immune milieu from one that is permissive to metastasis to one that is hostile to cancer growth. Feng’s study provides the mechanistic roadmap for designing just such a combination trial, though much needs to be unraveled about the kinetics of UPP1-driven macrophage polarization and the temporal dynamics of IL-1β release.
In the end, the study by Feng and colleagues is far more than a neat molecular story; it is a profound reminder that cancer is a disease of corrupted conversations between cells. The macrophage’s UPP1 enzyme is not mutated or malignant itself; it is simply responding to the biochemical whispers of its environment, amplifying a metabolic signal into an inflammatory shout that the cancer cells use as a departure cue. The discovery of this UPP1-mtROS-cGAS-NLRP3 axis elegantly connects dots from nucleotide biochemistry to mitochondrial biology, innate immunity, and clinical metastasis, offering a vivid illustration of the interconnected logic that underpins life’s most lethal diseases. It transforms UPP1 from an obscure enzyme into a new North Star for anti-metastatic drug discovery, shining a light on a path that, if successfully navigated, could finally help clinicians prevent the relentless seeding of cancer that claims so many lives. The long journey from bench to bedside has just begun, but the map suddenly looks far more detailed.
Subject of Research: Upregulation of macrophage UPP1 promotes lung adenocarcinoma metastasis through an mtROS-cGAS-NLRP3 inflammasome axis.
Article Title: Upregulation of macrophage UPP1 promotes lung adenocarcinoma metastasis through an mtROS-cGAS-NLRP3 inflammasome axis.
Article References:
Feng, M., Gao, C., Yang, Y. et al. Upregulation of macrophage UPP1 promotes lung adenocarcinoma metastasis through an mtROS-cGAS-NLRP3 inflammasome axis.
Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03226-4
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03226-4
Keywords: Lung adenocarcinoma, metastasis, tumor-associated macrophages, UPP1, uridine phosphorylase 1, mitochondrial reactive oxygen species, mtROS, cGAS, NLRP3 inflammasome, IL-1β, immunometabolism, innate immunity.
